nach oben

Erschienen in:

26.11.2019 | Review and Perspectives

Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas

verfasst von: Santiago Montes-Moreno, Rebecca L. King, Ilske Oschlies, Maurilio Ponzoni, John R. Goodlad, Snjezana Dotlic, Alexandra Traverse-Glehen, German Ott, Judith A. Ferry, Maria Calaminici

Erschienen in: Virchows Archiv | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

This paper summarizes two sessions of the workshop during the XIX meeting of the European Association for Haematopathology (EAHP) held in Edinburgh in September 2018 dedicated to lymphomas of the gastrointestinal tract. The first session focused on the clinical and pathological features of primary gastrointestinal T cell and NK-cell lymphoproliferative disorders. The distinction between precursor lesions (RCD type 2) and enteropathy-associated T cell lymphoma were stressed, including the discussion of new diagnostic markers for the identification of aberrant phenotypes. Indolent T cell lymphoproliferative disorders of the gastrointestinal tract cases showed phenotypic heterogeneity with novel molecular alterations in few cases, such as STAT3-JAK2 fusion. In addition, novel clonal markers of disease, such as AXL and JAK3 somatic variants support the neoplastic nature of NK-cell enteropathy. The session on gastrointestinal tract B cell lymphoproliferations was dedicated to B cell lymphoproliferative disorders that arise primarily in the gastrointestinal tract (i.e., duodenal-type follicular lymphoma) or preferentially involve the digestive tract, such as large B cell lymphoma with IRF4 translocation and mantle cell lymphoma (MCL), including diverse molecular subtypes (i.e., CCND3-positive MCL mimicking MALT lymphoma). Challenging cases of high-grade B cell lymphomas with complex genetic profiles demonstrated the usefulness of novel molecular diagnostic methods such as targeted NGS to identify high-risk genetic features with potential clinical impact.

Swerdlow SH CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition). IARC: Lyon; 2017

Perry AM, Warnke RA, Hu Q, Gaulard P, Copie-Bergman C, Alkan S, Wang HY, Cheng JX, Bacon CM, Delabie J, Ranheim E, Kucuk C, Hu X, Weisenburger DD, Jaffe ES, Chan WC (2013) Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood. 122(22):3599–3606PubMedPubMedCentral

Mansoor A, Pittaluga S, Beck PL, Wilson WH, Ferry JA, Jaffe ES (2011) NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood. 117(5):1447–1452PubMedPubMedCentral

Takeuchi K, Yokoyama M, Ishizawa S, Terui Y, Nomura K, Marutsuka K, Nunomura M, Fukushima N, Yagyuu T, Nakamine H, Akiyama F, Hoshi K, Matsue K, Hatake K, Oshimi K (2010) Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood. 116(25):5631–5637PubMed

Rubio-Tapia A, Murray JA (2010) Classification and management of refractory coeliac disease. Gut. 59(4):547–557PubMedPubMedCentral

Rubio-Tapia A, Kelly DG, Lahr BD, Dogan A, Wu TT, Murray JA (2009) Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology. 136(1):99–107 quiz 352-103PubMed

Malamut G, Afchain P, Verkarre V, Lecomte T, Amiot A, Damotte D, Bouhnik Y, Colombel JF, Delchier JC, Allez M, Cosnes J, Lavergne-Slove A, Meresse B, Trinquart L, Macintyre E, Radford-Weiss I, Hermine O, Brousse N, Cerf-Bensussan N, Cellier C (2009) Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology. 136(1):81–90PubMed

van Wanrooij RL, Müller DM, Neefjes-Borst EA, Meijer J, Koudstaal LG, Heideman DA, Bontkes HJ, von Blomberg B, Bouma G, Mulder CJ (2014) Optimal strategies to identify aberrant intra-epithelial lymphocytes in refractory coeliac disease. J Clin Immunol 34(7):828–835PubMed

Farstad IN, Johansen FE, Vlatkovic L, Jahnsen J, Scott H, Fausa O, Bjørneklett A, Brandtzaeg P, Halstensen TS (2002) Heterogeneity of intraepithelial lymphocytes in refractory sprue: potential implications of CD30 expression. Gut. 51(3):372–378PubMedPubMedCentral

10.

Cheminant M, Bruneau J, Malamut G et al (2018) NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study. Gut 68(8):1396–1405PubMed

11.

Ettersperger J, Montcuquet N, Malamut G, Guegan N, Lopez-Lastra S, Gayraud S, Reimann C, Vidal E, Cagnard N, Villarese P, Andre-Schmutz I, Gomes Domingues R, Godinho-Silva C, Veiga-Fernandes H, Lhermitte L, Asnafi V, Macintyre E, Cellier C, Beldjord K, di Santo JP, Cerf-Bensussan N, Meresse B (2016) Interleukin-15-dependent T-cell-like innate intraepithelial lymphocytes develop in the intestine and transform into lymphomas in celiac disease. Immunity. 45(3):610–625PubMed

12.

Tack GJ, van Wanrooij RL, Langerak AW, Tjon JM, von Blomberg B, Heideman DA, van Bergen J, Koning F, Bouma G, Mulder CJ, Schreurs MW (2012) Origin and immunophenotype of aberrant IEL in RCDII patients. Mol Immunol 50(4):262–270PubMed

13.

Malamut G, Chandesris O, Verkarre V, Meresse B, Callens C, Macintyre E, Bouhnik Y, Gornet JM, Allez M, Jian R, Berger A, Châtellier G, Brousse N, Hermine O, Cerf-Bensussan N, Cellier C (2013) Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig Liver Dis 45(5):377–384PubMedPubMedCentral

14.

Chan JK, Chan AC, Cheuk W, Wan SK, Lee WK, Lui YH, Chan WK (2011) Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent γδ T-cell receptor expression. Am J Surg Pathol 35(10):1557–1569PubMed

15.

Sun J, Lu Z, Yang D, Chen J (2011) Primary intestinal T-cell and NK-cell lymphomas: a clinicopathological and molecular study from China focused on type II enteropathy-associated T-cell lymphoma and primary intestinal NK-cell lymphoma. Mod Pathol 24(7):983–992PubMed

16.

Swerdlow SH, Jaffe ES, Brousset P, Chan JK, de Leval L, Gaulard P, Harris NL, Pileri S, Weiss LM, International Lymphoma Study Group (2014) Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol 38(10):e60–e71PubMedPubMedCentral

17.

Tan SY, Chuang SS, Tang T, Tan L, Ko YH, Chuah KL, Ng SB, Chng WJ, Gatter K, Loong F, Liu YH, Hosking P, Cheah PL, Teh BT, Tay K, Koh M, Lim ST (2013) Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8αα phenotype. Leukemia. 27(8):1688–1696PubMed

18.

Roberti A, Dobay MP, Bisig B et al (2016) Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. Nat Commun 7:12602PubMedPubMedCentral

19.

Kucuk C, Jiang B, Hu X et al (2015) Activating mutations of STAT5B and STAT3 in lymphomas derived from gamma delta-T or NK cells. Nat Commun 6:6025PubMed

20.

Moffitt AB, Ondrejka SL, McKinney M, Rempel RE, Goodlad JR, Teh CH, Leppa S, Mannisto S, Kovanen PE, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Iqbal J, Yu J, Naresh K, Villa D, Gascoyne RD, Said J, Czader MB, Chadburn A, Richards KL, Rajagopalan D, Davis NS, Smith EC, Palus BC, Tzeng TJ, Healy JA, Lugar PL, Datta J, Love C, Levy S, Dunson DB, Zhuang Y, Hsi ED, Dave SS (2017) Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. J Exp Med 214(5):1371–1386PubMedPubMedCentral

21.

Carbonnel F, Lavergne A, Messing B, Tsapis A, Berger R, Galian A, Nemeth J, Brouet JC, Rambaud JC (1994) Extensive small intestinal T-cell lymphoma of low-grade malignancy associated with a new chromosomal translocation. Cancer. 73(4):1286–1291PubMed

22.

Sharma A, Oishi N, Boddicker RL, Hu G, Benson HK, Ketterling RP, Greipp PT, Knutson DL, Kloft-Nelson SM, He R, Eckloff BW, Jen J, Nair AA, Davila JI, Dasari S, Lazaridis KN, Bennani NN, Wu TT, Nowakowski GS, Murray JA, Feldman AL (2018) Recurrent STATJAK2 fusions in indolent T-cell lymphoproliferative dis-order of the gastrointestinal tract. Blood. 131(20):2262–2266PubMedPubMedCentral

23.

Soderquist CR, Patel N, Murty VV et al (2019) Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract. Haematologica

24.

Perry AM, Bailey NG, Bonnett M, Jaffe ES, Chan WC (2019) Disease progression in a patient with indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Int J Surg Pathol 27(1):102–107PubMed

25.

Margolskee E, Jobanputra V, Lewis SK, Alobeid B, Green PH, Bhagat G (2013) Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features. PLoS One 8(7):e68343PubMedPubMedCentral

26.

Matnani R, Ganapathi KA, Lewis SK, Green PH, Alobeid B, Bhagat G (2017) Indolent T- and NK-cell lymphoproliferative disorders of the gastrointestinal tract: a review and update. Hematol Oncol 35(1):3–16PubMed

27.

Vega F, Chang CC, Schwartz MR et al (2006) Atypical NK-cell proliferation of the gastrointestinal tract in a patient with antigliadin antibodies but not celiac disease. Am J Surg Pathol 30(4):539–544PubMed

28.

Xiao W, Gupta GK, Yao J, Jang YJ, Xi L, Baik J, Sigler A, Kumar A, Moskowitz AJ, Arcila ME, Raffeld M, Pittaluga S, Dogan A, Jaffe ES (2019) Recurrent somatic JAK3 mutations in NK-cell enteropathy. Blood. 134(12):986–991PubMed

29.

Caraux A, Lu Q, Fernandez N, Riou S, di Santo JP, Raulet DH, Lemke G, Roth C (2006) Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nat Immunol 7(7):747–754PubMed

30.

Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F, Fededa JP, Cronin SJ, Nitsch R, Schultz-Fademrecht C, Eickhoff J, Menninger S, Unger A, Torka R, Gruber T, Hinterleitner R, Baier G, Wolf D, Ullrich A, Klebl BM, Penninger JM (2014) The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 507(7493):508–512PubMedPubMedCentral

31.

Takata K, Sato Y, Nakamura N, Tokunaka M, Miki Y, Yukie Kikuti Y, Igarashi K, Ito E, Harigae H, Kato S, Hayashi E, Oka T, Hoshii Y, Tari A, Okada H, al-Kader LA, Maeda Y, Tanimoto M, Kinoshita T, Yoshino T (2013) Duodenal follicular lymphoma lacks AID but expresses BACH2 and has memory B-cell characteristics. Mod Pathol 26(1):22–31PubMed

32.

Hellmuth JC, Louissaint A, Szczepanowski M et al (2018) Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. Blood. 132(16):1695–1702PubMed

33.

Adam P, Baumann R, Schmidt J, Bettio S, Weisel K, Bonzheim I, Fend F, Quintanilla-Martínez L (2013) The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-“negative” grade 1/2 follicular lymphomas. Hum Pathol 44(9):1817–1826PubMed

34.

Mamessier E, Song JY, Eberle FC, Pack S, Drevet C, Chetaille B, Abdullaev Z, Adelaïde J, Birnbaum D, Chaffanet M, Pittaluga S, Roulland S, Chott A, Jaffe ES, Nadel B (2014) Early lesions of follicular lymphoma: a genetic perspective. Haematologica. 99(3):481–488PubMedPubMedCentral

35.

Takata K, Tanino M, Ennishi D, Tari A, Sato Y, Okada H, Maeda Y, Goto N, Araki H, Harada M, Ando M, Iwamuro M, Tanimoto M, Yamamoto K, Gascoyne RD, Yoshino T (2014) Duodenal follicular lymphoma: comprehensive gene expression analysis with insights into pathogenesis. Cancer Sci 105(5):608–615PubMedPubMedCentral

36.

Kiess AP, Yahalom J (2013) Primary follicular lymphoma of the gastrointestinal tract: effect of stage, symptoms and treatment choice on outcome. Leuk Lymphoma 54(1):177–180PubMed

37.

Takata K, Okada H, Ohmiya N, Nakamura S, Kitadai Y, Tari A, Akamatsu T, Kawai H, Tanaka S, Araki H, Yoshida T, Okumura H, Nishisaki H, Sagawa T, Watanabe N, Arima N, Takatsu N, Nakamura M, Yanai S, Kaya H, Morito T, Sato Y, Moriwaki H, Sakamoto C, Niwa Y, Goto H, Chiba T, Matsumoto T, Ennishi D, Kinoshita T, Yoshino T (2011) Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: a multicenter, retrospective analysis in Japan. Cancer Sci 102(8):1532–1536PubMed

38.

Tari A, Kitadai Y, Mouri R, Takigawa H, Asaoku H, Mihara K, Takata K, Fujihara M, Yoshino T, Koga T, Fujimori S, Tanaka S, Chayama K (2018) Watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma. J Gastroenterol Hepatol 33(8):1461–1468PubMed

39.

Schmatz AI, Streubel B, Kretschmer-Chott E, Püspök A, Jäger U, Mannhalter C, Tiemann M, Ott G, Fischbach W, Herzog P, Seitz G, Stolte M, Raderer M, Chott A (2011) Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol 29(11):1445–1451PubMed

40.

Sentani K, Maeshima AM, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y (2008) Follicular lymphoma of the duodenum: a clinicopathologic analysis of 26 cases. Jpn J Clin Oncol 38(8):547–552PubMed

41.

Kitabatake H, Nagaya T, Tanaka N, Ota H, Sano K, Asano N, Suga T, Nakamura Y, Akamatsu T, Tanaka E (2017) Development of diffuse large B-cell lymphoma from follicular lymphoma of the duodenum: changes in endoscopic findings during a 6-year follow-up. Clin J Gastroenterol 10(1):79–85PubMed

42.

Miyata-Takata T, Takata K, Sato Y, Taniguchi K, Takahashi Y, Ohara N, Yoshino T (2014) A case of diffuse large B-cell lymphoma transformed from primary duodenal follicular lymphoma. Pathol Int 64(10):527–532PubMed

43.

Salaverria I, Royo C, Carvajal-Cuenca A et al (2013) CCND2 rearrangements are the most frequent genetic events in cyclin D1(−) mantle cell lymphoma. Blood. 121(8):1394–1402PubMedPubMedCentral

44.

Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, Chiorazzi M, Iqbal J, Gesk S, Siebert R, de Jong D, Jaffe ES, Wilson WH, Delabie J, Ott G, Dave BJ, Sanger WG, Smith LM, Rimsza L, Braziel RM, Müller-Hermelink HK, Campo E, Gascoyne RD, Staudt LM, Chan WC, Lymphoma/Leukemia Molecular Profiling Project (2005) Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 106(13):4315–4321PubMedPubMedCentral

45.

Martín-Garcia D, Navarro A, Valdés-Mas R, Clot G, Gutiérrez-Abril J, Prieto M, Ribera-Cortada I, Woroniecka R, Rymkiewicz G, Bens S, de Leval L, Rosenwald A, Ferry JA, Hsi ED, Fu K, Delabie J, Weisenburger D, de Jong D, Climent F, O’Connor SJ, Swerdlow SH, Torrents D, Beltran S, Espinet B, González-Farré B, Veloza L, Costa D, Matutes E, Siebert R, Ott G, Quintanilla-Martinez L, Jaffe ES, López-Otín C, Salaverria I, Puente XS, Campo E, Beà S (2019) CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1 - mantle cell lymphoma. Blood. 133(9):940–951PubMedPubMedCentral

46.

Quintanilla-Martinez L, Thieblemont C, Fend F, Kumar S, Pinyol M, Campo E, Jaffe ES, Raffeld M (1998) Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 153(1):175–182PubMedPubMedCentral

47.

Fernandez V, Salamero O, Espinet B et al (2010) Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70(4):1408–1418PubMed

48.

Ondrejka SL, Lai R, Smith SD, Hsi ED (2011) Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica. 96(8):1121–1127PubMedPubMedCentral

49.

Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, Burkhardt B, Trautmann H, Gesk S, Andrusiewicz M, Berger H, Fey M, Harder L, Hasenclever D, Hummel M, Loeffler M, Mahn F, Martin-Guerrero I, Pellissery S, Pott C, Pfreundschuh M, Reiter A, Richter J, Rosolowski M, Schwaenen C, Stein H, Trümper L, Wessendorf S, Spang R, Küppers R, Klapper W, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe, German High-Grade Lymphoma Study Group, Berlin-Frankfurt-Münster-NHL trial group (2011) Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 118(1):139–147PubMed

50.

Liu Q, Salaverria I, Pittaluga S, Jegalian AG, Xi L, Siebert R, Raffeld M, Hewitt SM, Jaffe ES (2013) Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol 37(3):333–343PubMedPubMedCentral

51.

de Leval L, Bonnet C, Copie-Bergman C, Seidel L, Baia M, Brière J, Molina TJ, Fabiani B, Petrella T, Bosq J, Gisselbrecht C, Siebert R, Tilly H, Haioun C, Fillet G, Gaulard P (2012) Diffuse large B-cell lymphoma of Waldeyer’s ring has distinct clinicopathologic features: a GELA study. Ann Oncol 23(12):3143–3151PubMed

52.

Zenz T, Kreuz M, Fuge M, Klapper W, Horn H, Staiger AM, Winter D, Helfrich H, Huellein J, Hansmann ML, Stein H, Feller A, Möller P, Schmitz N, Trümper L, Loeffler M, Siebert R, Rosenwald A, Ott G, Pfreundschuh M, Stilgenbauer S, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) (2017) TP53 mutation and survival in aggressive B cell lymphoma. Int J Cancer 141(7):1381–1388PubMed

53.

Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken J, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Kahl BS, Winter JN, Xu W, Li J, Go RS, Li Y, Piris MA, Møller MB, Miranda RN, Abruzzo LV, Medeiros LJ, Young KH (2012) Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 120(19):3986–3996PubMedPubMedCentral

54.

Clipson A, Barrans S, Zeng N, Crouch S, Grigoropoulos NF, Liu H, Kocialkowski S, Wang M, Huang Y, Worrillow L, Goodlad J, Buxton J, Neat M, Fields P, Wilkins B, Grant JW, Wright P, Ei-Daly H, Follows GA, Roman E, Watkins AJ, Johnson PW, Jack A, du MQ (2015) The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. J Pathol Clin Res 1(3):125–133PubMedPubMedCentral

Titel: Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas
verfasst von: Santiago Montes-Moreno
Rebecca L. King
Ilske Oschlies
Maurilio Ponzoni
John R. Goodlad
Snjezana Dotlic
Alexandra Traverse-Glehen
German Ott
Judith A. Ferry
Maria Calaminici
Publikationsdatum: 26.11.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 5/2020
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-019-02704-8

Springer Medizin

Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis

In this issue

The clinico-pathological spectrum of primary cutaneous lymphoma other than mycosis fungoides/Sezary syndrome

Lymphoproliferations at extranodal sites: a morphologically, genetically, and clinically diverse group of neoplasms with overlapping features

Primary pulmonary myxoid sarcoma with an unusual gene fusion between exon 7 of EWSR1 and exon 5 of CREB1

High homogeneity of mismatch repair deficiency in advanced prostate cancer

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie